2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2017 Symposium


The 13th Moores Cancer Center Industry/Academia Translational Oncology Symposium will be held on Thursday, February 16, 2017. Save the date!

Keynote Speaker

Owen N. Witte, MD

Director, UCLA Broad Stem Cell Research Center
Distinguished Professor of Microbiology, Immunology and Molecular Genetics
University of California, Los Angeles
Investigator, Howard Hughes Medical Institute

Anthony Gringeri, PhD

Senior Vice President, Strategic Resources
ImmunoCellular Therapeutics



2016 Symposium Featured Talks


Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Moores Cancer Center Welcome


Ezra Cohen, MD
UC San Diego Moores Cancer Center




Duane Roth Award


Presented by Council President Sherri Lightner, City of San Diego
Awarded to Dennis Slamon, MD, PhD, UCLA Jonsson Comprehensive Cancer Center


Lung cancer KRAS addiction is reversed by disrupting an integrin/lectin membrane complex


David Cheresh, PhD
UC San Diego Moores Cancer Center



Keynote Presentation: Molecular diversity of human breast cancer: biologic and therapeutic implications


Dennis Slamon, MD, PhD
UCLA Jonsson Comprehensive Cancer Center


Immuno-Oncology: Rational combination therapy


Chris Boshoff, MD, PhD
Pfizer




Detection and targeting of malignant niche mediated cancer stem cell generation


Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center



The role of the microenvironment in modulating tumor angiogenesis


Napeoleone Ferrara, MD
UC San Diego Moores Cancer Center



Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody


Victoria Smith, PhD
Gilead Sciences



The bone niche and therapy resistance in bone metastatic prostate cancer


Christina Jamieson, PhD
UC San Diego Moores Cancer Center



Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic


J. Silvio Gutkind, PhD
UC San Diego Moores Cancer Center



Anti-ErbB3 therapies – what do we know to date


Birgit Schoeberl, PhD
Merrimack Pharmaceuticals




Immunotherapy Program at UC San Diego Moores Cancer Center


Ezra Cohen, MD
UC San Diego Moores Cancer Center



Compound development of LADD therapeutics in lung cancer


Robert Charnas, PhD
Janssen R&D



Towards personalized immunotherapy of HNSCC


Stephen Schoenberger, PhD
La Jolla Institute for Allergy and Immunology, Human Longevity Inc.



A platform to discover immunotherapeutics for cancer


Judith Varner, PhD
UC San Diego Moores Cancer Center



Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy


Tony Polverino, PhD
Kite Pharma


Partnering with patients to accelerate the pace of biomedical research


Corrie Painter, PhD
Broad Institute of MIT and Harvard



The role of MET exon14 deletion mutations as driver oncogenes in patients with NSCLC and therapeutic intervention with the prototype MET inhibitor glesatinib


James Christensen, PhD
Mirati Therapeutics


Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations


Deborah Morosini, MD
Foundation Medicine


Monitoring daily dynamics of early tumor response to targeted therapy in lung cancer


Hatim Husain, MD
UC San Diego Moores Cancer Center
Mark Erlander, PhD
Trovagene


Closing Remarks


Catriona Jamieson, MD, PhD
UC San Diego Moores Cancer Center




Anti-cancer therapies derived from human pluripotent stem cells


Dan Kaufman, PhD
UC San Diego Moores Cancer Center



Symposium Organizer Welcome


Ida Deichaite, PhD
UC San Diego Moores Cancer Center






2016 Symposium Information


KEYNOTE SPEAKERS

Polyvalent vaccines targeting oncogenic driver pathways

Nora Disis, MD

Adjunct Professor of Pathology and Obstetrics and Gynecology
Fred Hutchinson Cancer Research Center
Associate Dean for Translational Science
University of Washington School of Medicine

Molecular diversity of human breast cancer: biologic and therapeutic implications

Dennis Slamon, MD, PhD

Director, Clinical/Translational Research
UCLA Jonsson Comprehensive Cancer Center


FEATURED SPEAKERS

Translational studies of KTN3379, a novel anti-ErbB3 antibody

Diego Alvarado, PhD

Associate Director of Research
Kolltan Pharmaceuticals

Immuno-Oncology: Rational combination therapy

Chris Boshoff, MD, PhD

Vice President, Early Development, Translational and Immuno-Oncology
Pfizer, Inc.

Compound development of LADD therapeutics in prostate and lung cancer

Robert Charnas, PhD

Compound Development Team Leader
Janssen R&D

Lung cancer KRAS addiction is reversed by disrupting an integrin/lectin membrane complex

David Cheresh, PhD

UC San Diego Moores Cancer Center

The role of MET exon14 deletion mutations as driver oncogenes in patients with NSCLC and therapeutic intervention with the prototype MET inhibitor glesatinib

Jamie Christensen, PhD

Chief Scientific Officer
Mirati Therapeutics

Overview

Ezra Cohen, MD

UC San Diego Moores Cancer Center

Monitoring daily dynamics of early tumor response to targeted therapy in lung cancer

Hatim Husain, MD

UC San Diego Moores Cancer Center

Mark Erlander, PhD

Chief Scientific Officer
Trovagene

The role of the microenvironment in modulating tumor angiogenesis

Napoleone Ferrara, MD

UC San Diego Moores Cancer Center

Targeting the PI3K-mTOR signaling circuitry in cancer: a bridge from bench to clinic

J. Silvio Gutkind, PhD

UC San Diego Moores Cancer Center

Detection and targeting of malignant niche mediated cancer stem cell generation

Catriona Jamieson, MD, PhD

UC San Diego Moores Cancer Center

The bone niche and therapy resistance in bone metastatic prostate cancer

Christina Jamieson, PhD

UC San Diego Moores Cancer Center

Anti-cancer therapies derived from human pluripotent stem cells

Dan Kaufman, MD, PhD

UC San Diego Moores Cancer Center

In the wake of homologous repair deficiency: Identifying PARP inhibitor responsive patients

Keith Mikule, PhD

Director, Preclinical Research
TESARO

Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations

Deborah Morosini, MD

Vice President, Clinical Affairs and Patient Engagement
Foundation Medicine

Partnering with patients to accelerate the pace of biomedical research

Corrie Painter, PhD

Associate Director of Operations and Scientific Outreach
Broad Institute of MIT and Harvard

Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy

Tony Polverino, PhD

Vice President, Research
Kite Pharma

Anti-ErbB3 therapies – what do we know to date

Birgit Schoeberl, PhD

SVP, Head of Discovery
Merrimack

Towards personalized immunotherapy of HNSCC

Stephen Schoenberger, PhD

Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology
Head of Cancer Vaccines, Human Longevity Inc.

Revisiting matrix metalloproteinases: allosteric inhibition of MMP9 using a monoclonal antibody

Victoria Smith, PhD

Senior Director, Biology
Gilead Sciences

A platform to discover immunotherapeutics for cancer

Judith Varner, PhD

UC San Diego Moores Cancer Center





ABOUT THIS SYMPOSIUM

Contemporary leaders of oncology are driven to redefine the notion of curative medicine by skillfully leveraging the power of collaboration to optimize everyone’s unique expertise and stretch research dollars in order to drive innovation. They are also changing clinical trial paradigms and emphasizing combination immunotherapy, new therapeutic modalities, and precision diagnosis. Already, as a result of these efforts, the oncology community can treat cancer patients and combat cancer at the molecular level.

The annual Industry/Academia Translational Oncology Symposium at Moores Cancer Center, now celebrating its 12th year, was created to support multi-modality collaborations and foster new partnerships in order to speed new therapies to patients. Each year the Symposium’s esteemed presenters from around the world, including clinicians, researchers, and top decision makers from industry and academia, attest to just how necessary it was for them to surmount multiple obstacles, in and out of the lab, in order to achieve success and help patients. The forum provides a platform for oncology innovators to highlight their interdisciplinary approach, as opposed to discussion on a specific type of cancer. Case study presentations showcase successful efforts, the challenges that they encountered, and the lessons they have learned from the process.

SYMPOSIUM FORMAT

To address the need for dialogue amongst all leaders of cancer research, the Symposium promotes interaction and discussion throughout the entire program. Invited speakers give presentations that range in length, and include a keynote presentation, numerous presenters from faculty and industry, young investigator presentation, interactive discussion panels, and poster sessions, highlighting rapidly emerging cancer science. Discussions continue throughout breaks and lunch, and culminate in a networking reception. Additionally, a dinner consisting of Symposium speakers and sponsors held prior to the event creates an opportunity for introductions to be made and work to be discussed in a relaxed, collegial setting. Through the Symposium’s emphasis on translational oncology and drug development, we shepherd researchers and physicians to foster fruitful, ongoing relationships and partnerships with local, regional, and national biotechnology and pharmaceutical companies, ultimately resulting in curative therapies that advance global cancer treatment paradigms.

TARGET AUDIENCE

The field of oncology is brimming with innovators and investigators ready to blaze new pathways for bringing the most effective novel therapies out of the laboratory to the patients. Clinicians, researchers, and top decision makers are critical in the process of translation to deliver curative cancer therapies. Our goal is to unite these individuals and provide a forum through which they can network and collaborate, while celebrating the community’s successful efforts.

TOPICS WILL INCLUDE

  • Immunotherapy
  • Precision medicine
  • New therapeutic approaches in numerous cancers
  • Orphan drug oncology indications
  • Innovative clinical trial modalities
  • Funding innovation


ABOUT THE LOCATION

San Diego provides an ideal environment for successful partnerships and collaborations: The intersection of academia, biomedical research, top-notch health care providers, and entrepreneurship allow innovation to abound. San Diego’s position as a global hub for biomedical innovation serves as a role model for translational oncology on a national level.




Symposium Organizers and Chairs


Symposium Organizers:

Scott Lippman, MD
Director
UCSD Moores Cancer Center


Symposium Chair:

David Cheresh, PhD
Associate Director for Innovation and Industry Alliances,
Distinguished Professor of Pathology
UCSD Moores Cancer Center


Symposium Co-Chair:

Judith Varner, PhD
Professor of Pathology
UCSD Moores Cancer Center


Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center


Symposium Co-Chair:

Catriona Jamieson, MD, PhD
Associate Professor of Medicine,
Chief, Division of Regenerative Medicine
Deputy Director, Sanford Stem Cell Clinical Center
Director, Moores Cancer Center Stem Cell Research Program
UCSD Moores Cancer Center











We Thank Our Sponsors: